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E-5-Propenyl-2'-deoxyuridine (E-5-propenyl-dUrd) inhibited the growth of
herpes simplex virus (HSV) types 1 (HSV-1) and 2 in culture. The concentration
of drug required to give a 2-log reduction in virus titer was 5 JIM for HSV-1 and
23 /LM for HSV-2. The anti-HSV-1 activity of this agent was more potent than 5-
propyl-dUrd, equivalent to E-5-(3,3,3-trifluoropropenyl)-dUrd, and less potent
than E-5-bromovinyl-dUrd. The HSV-1 mutant (B2006) lacking the ability to
induce virus-specific thymidine kinase could not be inhibited by E-5-propenyl-
dUrd. The binding constants of E-5-propenyl-dUrd to HSV-1, HSV-2, varicella-
zoster virus, and human mitochondrial thymidine kinases were established to be
0.2, 6.2, 0.3, and 0.8 tiM, respectively. Thymidine phosphorylation catalyzed by
human cytosol thymidine kinase could not be inhibited by E-5-propenyl-dUrd at
a concentration 10-fold higher than the thymidine in the assay. When thymidine
and E-5-propenyl-dUrd were added concomitantly at equal concentrations to
virus-infected cells, the antiviral activity was not reversed in HSV-1 and only
partially reversed in HSV-2. E-5-Propenyl-dUrd also inhibited the growth of
human cells in culture with 50% inhibitory dose of 50 ,uM. Since this inhibition
could be readily reversed by a lower concentration of thymidine, the idea of
selective protection is proposed. This approach could avoid the cytotoxic effect of
an antiviral agent with properties similar to E-5-propenyl-dUrd without sacrific-
ing antiviral activity.
Since we first postulated the concept of selec-
tive alternative substrate approach for the ra-
tional development of selective anti-herpes sim-
plex virus (HSV) agents (2), a large number of
thymidine (dThd) or deoxycytidine analogs with
a modification at the 5 position were synthesized
and examined for their antiviral activity (9, 18).
Some of these analogs have shown more potent
anti-HSV effects than 5-propyl- or 5-ethyl-2'-
deoxyuridine (5-ethyl-dUrd), which were used
as the examples for demonstrating specific alter-
native substrate approach (4). Unfortunately, all
of these analogs have some degree of toxicity
against cell growth in culture which could limit
their potential use and safety in the clinic. In-
stead of trying to further modify these com-
pounds, ideally the uninfected cells could be
protected against the cytotoxicity of these nu-
cleoside analogs without sacrificing their anti-
viral effects. This is why two approaches were
postulated by which cytotoxicity could be
avoided. The first, the selective inhibitor ap-
proach (3), was independently proven to be ef-
fective by Fisher et al. (11) with the combination
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of iodo-dUrd and 5'-aminothymidine. The sec-
ond, the selective protection approach, is de-
scribed in this report with a newly synthesized
drug, E-5-propenyl-dUrd. Although this paper
deals with the cytotoxicity and antiviral activity
of this compound, this selective protection ap-




propenyl-dUrd, and 5-propyl-dUrd were synthesized
by the procedure described previously (17, 19). E-5-
Bromovinyl-dUrd was kindly provided by D. Walker
of the University of Birmingham, England, and E.
DeClercq of the Rega Institute for Medical Research,
Belgium. dThd was purchased from P-L Biochemicals,
Inc.
Enzymes. Human cytosol and mitochondrial thy-
midine kinases were extracted from peripheral blasts
of acute myelocytic leukemia patients. HSV type 1
(HSV-1) and HSV-2 thymidine kinases were purified
from virus-infected HeLa BU (cytosol thymidine ki-
nase deficient) cells 16 h postinfection. The procedures
for purifying different types of thymidine kinase by
affinity column chromatography and the enzyme assay
were described previously (5, 14). Enzyme amounts of
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from 5 x 10-2 to 1.0 x 10-2 U were used for determining
the Ki values of different analogs.
Cells. The cells were grown at 37°C in RPMI 1640
medium containing 100,ug of kanamycin per ml and
supplemented with 5% calf serum for CV-1 and HeLa
BU cells and 5% fetal calf serum for HeLa and KB
cells. All cultures were found to be mycoplasma free
when tested by the 4,6-diamidino-2-phenylindole flu-
orescence technique (16).
Virus stocks. HSV-1 (strains KOS and B2006) or
HSV-2 (strain 333) was added at a low multiplicity of
infection (0.1 plaque-forming unit [PFU] per cell) to
150-cm2 flasks of confluent CV-1 monolayers. After a
1-h adsorption period, 40 ml of RPMI 1640 supple-
mented with 5% calf serum was added. The cells were
then incubated at 37°C for 24 h, followed by incubation
at 34°C for 48 (HSV-1) or 24 h (HSV-2). At the end of
this incubation period, the cells were suspended and
aliquoted into sterile plastic tubes (12 by 75 mm) and
kept frozen until titration. The yield of virus under
these conditions was at least 5 x 10' PFU/ml.
Thymidine kinase was induced in infected HeLa
BU cells by strains KOS and 333 but not by B2006.
Cell and virus growth inhibition. The cells were
seeded in 25-cm2 flasks in their respective growth
media. They were then incubated for 24 h before
adding the drug to allow the cells time to attach to the
flask and to ensure that they were in log phase. The
cell number was determined at the time of drug addi-
tion and 24, 48, and 72 h later by hemacytometer
counts. All cell numbers were determined by an aver-
age of at least two flasks for each condition.
Confluent HeLa BU cells in 25-cm2 flasks were used
as host cells for virus infection. After a 1-h adsorption
period of virus at 5 to 10 PFU per cell, the monolayers
were rinsed twice with phosphate-buffered saline fol-
lowed by addition of 5 ml ofgrowth medium containing
various concentrations of drug. The cells were incu-
bated at 37°C for 28 h, then stored frozen at -70°C
until titration. A suspension of CV-1 cells containing
0.1% methylcellulose (15 cps) was added to sterile 24-
well plates and incubated at 37°C for 24 h. A serial
dilution was prepared with complete growth medium
from the virus samples. The medium was removed
from the CV-1 monolayers, and 100 of the virus
dilutions was added to each well. The plates were
incubated for 1 h at 37°C. This was followed by adding
to each well 0.5 ml of a mixture containing equal parts
of 2x growth medium and 2% methylcellulose (4,000
cps). After a 2-day incubation, the medium-methyl-
cellulose overlay was aspirated off and replaced with
0.25 ml of a 0.8% crystal violet solution in 50% ethanol.
After 10 min the stain was removed, and the plates
were rinsed with water. They were then allowed to air
dry, and the plaques were counted by the use of a light
box. Two duplicate trials were carried out to ensure
reproducibility.
RESULTS
Affinity of E-5-propenyl-dUrd to human-
and virus-induced thymidine kinases.
When E-5-propenyl-dUrd was examined against
various types of thymidine kinase, the drug
could not inactivate any of these enzymes. This
was demonstrated by preincubating thymidine
kinase with 0.5 mM ofE-5-propenyl-dUrd in the
presence of 2 mM adenosine triphosphate for 30
min at 37°C, where no enzyme activity was lost
during the incubation (data not shown). Yet this
drug acted as a competitive inhibitor against
["C]dThd phosphorylation catalyzed by human
mitochondria, HSV-1, HSV-2, and varicella-zos-
ter virus thymidine kinases. The Ki values are
reported in Table 1. E-5-Propenyl-dUrd could
not inhibit ["C]thymidine phosphorylation cat-
alyzed by human cytosol enzyme at a concentra-
tion ten times higher than the concentration of
dThd (100 ,uM) in the assay.
Effects ofE-5-propenyl-dUrd and related
analogs on HSV growth. The antiviral effects
ofE-5-propenyl-dUrd and related analogs on the
growth of HSV-1 (KOS), HSV-2 (333), and HSV-
1 thymidine kinase-deficient (TK-) mutant
(B2006) in HeLa BU cells were compared (Table
2). E-5-Bromovinyl-dUrd, which was shown pre-
viously to have potent anti-HSV-1 effects (8),
TABLE 1. Inhibition constant of E-5-propenyl-dUrd
for thymidine kinase derived from various sourcesa
Enzyme source Ki (PM)
Human cytosol ....... ....... >400'
Human mitochondria .............. 0.8
HSV-1 .............. 0.2
HSV-2 .............. 6.2
Varicella-zoster virus .............. 0.3c
a Thymidine kinase from various sources was puri-
fied with the procedures as described previously (1, 5).
Ki values were obtained with the same method as
described (8). Competitive inhibition of ['4C]dThd
phosphorylation by E-5-propenyl-dUrd catalyzed by
various isozymes was observed.
b Values obtained based on the sensitivity of our
assay.
'This Ki value, published previously (7), is included
for comparison.
TABLE 2. Effects of E-5-propenyl-dUrd and related
analogs on virus growth'
Control PFU/ml (%)
Additives (10,uM) HSV-1 HSV-2 HSV-1
(KOS) (333) (TK200)
None 100 100 100
5-Propyl-dUrd 7 9 107




a Drugs were added at 0 h postinfection, and viruses
were harvested at 28 h postinfection and titrated as
described in the text. The number ofPFU per milliliter
in control assays was 5.1 x 105 for HSV-1, 2.5 x 107 for
HSV-2, and 2.4 x 108 for HSV-1 TK-.
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was more potent than E-5-propenyl-dUrd, E-5-
(3,3,3-trifluoropropenyl)-dUrd, or 5-propyl-
dUrd against HSV-1 growth; all four compounds
exhibited comparable activity (within an order
of magnitude) against HSV-2 growth in HeLa
BU cells. The HSV-1 TK- mutant, which lacked
the ability to induce virus-specific thymidine
kinase, could not be inhibited by E-5-propenyl-
dUrd. The concentration-dependent inhibition
of virus growth by E-5-propenyl-dUrd is shown
in Fig. 1. The difference in the potency of E-5-
propenyl-dUrd against HSV-1, HSV-2, or HSV-
1 TK- growth in HeLa BU is clearly demon-
strated.
Effects ofE-5-propenyl-dUrd and related
analogs on human cell growth. KB cells were
grown in culture as described, and the effects of
E-5-propenyl-dUrd and related analogs on the
growth ofKB cells were examined (Tables 3 and
4). At 50 IM, 5-propyl-dUrd could not inhibit
KB cell growth, whereas E-5-propenyl-dUrd, E-
5-(3,3,3-trifluoropropenyl)-dUrd, and E-5-bro-
movinyl-dUrd could inhibit the cell growth
about 50%. The anti-cell growth potency was the












0 10 20 30 40 50
E-5-PROPENYL dUrd (pM)
FIG. 1. E-5-Propenyl-dUrd was added to HeLa
BU cells at 0 h postinfection. Viruses were harvested
and titrated 28 h postinfection as described in the
text.
growth inhibitory activity of E-5-propenyl-dUrd
on KB cells could be reversed by using one-fifth
the concentration of dThd (Table 3).
Effects of dThd on the antiviral activity
of E-5-propenyl-dUrd. dThd was added to
virus-infected cell cultures which contained 10
and 25 ltM E-5-propenyl-dUrd for HSV-1 and
HSV-2, respectively. Its effect on the inhibitory
activity of E-5-propenyl-dUrd on virus growth
was evaluated (Table 5). Whereas dThd at equi-
molar to four times the concentration of E-5-
propenyl-dUrd could only partially reverse the
antiviral effect of the drug in HSV-2, 10 times
more dThd than drug could not reverse the
action on HSV-1 growth. This may be related to
the fact that dThd could prevent the phospho-
rylation of E-5-propenyl-dUrd by HSV-2 thy-
midine kinase more efficiently than by HSV-1
thymidine kinase (Table 1).
DISCUSSION
The antiviral activity of E-5-propenyl-dUrd is
not dependent on the activity of cytosol thymi-
dine kinase since similar antiviral activity was
observed when HeLa or HeLa BU cells were
used as the host cells for HSV-1 and HSV-2
TABLE 3. Effects of 5-propenyl-dUrd and related
analogs on human KB cell grotvtha
Concn ~~CellAdditive Concn growth
None 100.0 ± 0
dThd 10 96.3 ± 5
5-Propyl-dUrd 50 99.8 ± 1
E-5-Propenyl-dUrd 50 43.8 ± 8
E-5-Trifluoro- 50 54.2 ± 3
propenyl-dUrd
E-5-Bromovinyl-dUrd 50 48.1 ± 3
E-5-Propenyl-dUrd 50 + 10 96.3 ± 5
+ dThd
a KB cells were grown under the conditions as de-
scribed in the text for 48 h. The percentages of cell
growth were compared with control, which increased
cell number 3.2-fold in comparison with the initial
number.
TABLE 4. Inhibitory effect of E-5-propenyl-dUrd on
the growth ofhuman KB cells'
Cell no. (x105) per flask at
Concn time postinoculation (h):
(PM)
0 24 48 72
None 0.6 1.3 2.8 5.2
25 0.6 0.9 2.1 3.4
50 0.6 0.8 1.5 2.9




TABLE 5. Effects ofdThd on antiviral activity of E-
5-propenyl-dUrd"
E-5-Pro- dThd Control PFU/rnl (%)
penyl-dUrd (HSM)(JM) HSV-1 HSV-2
None None 100 100











aE-5-Propenyl-dUrd or dThd or both were added
at 0 h postinfection. Viruses were harvested 28 h
postinfection and titrated as described in the text. The
PFU per milliliter for control assays was 3.8 x 108 for
HSV-1 and 1.9 x 107 for HSV-2.
infection (data not shown). This is consistent
with the observation that the cytosol thymidine
kinase had very poor binding affinity to E-5-
propenyl-dUrd (Table 1). The antiviral activity
of this drug seems to be related to its binding
affinity to viral thymidine kinase, based on the
following observations: E-5-propenyl-dUrd has
more affinity to HSV-1 thymidine kinase than
to HSV-2 thymidine kinase, and the antiviral
activity of E-5-propenyl-dUrd was more potent
against HSV-1 than HSV-2, whereas 5-propyl-
dUrd had similar binding affinity to HSV-1 and
HSV-2 thymidine kinases and similar antiviral
activity against HSV-1 and HSV-2 growth in
culture (Tables 1 and 2). The HSV-1 TK- mu-
tant lacking the ability to induce viral thymidine
kinase upon its infection was insensitive to either
5-propenyl-dUrd or 5-propyl-dUrd. It should be
noted that the specificity of thymidine kinase is
only a first-line determining factor for dThd
analogs; their potency against virus growth will
also depend on the behavior of their phospho-
rylated derivatives on the metabolic targets. In
general, the substrate specificity of HSV-1 or
varicella-zoster virus thymidine kinase is less
than HSV-2 thymidine kinase, as was suggested
previously (1, 6, 15). This is also consistent with
the observation in Table 1. Therefore, a dThd
analog which was shown to have activity against
HSV-1 would not always have equal activity
against HSV-2. The detailed interactions of E-
5-propenyl-dUrd will be examined when the ra-
dioactive compound becomes available.
The inhibitory effects of E-5-propenyl-dUrd
on the growth of human cells in culture may be
related to its strong binding affinity to human
mitochondrial thymidine kinase. HeLa BU cells,
which are deficient in cytosol thymidine kinase,
have a sensitivity to E-5-propenyl-dUrd similar
to that of HeLa or KB cells. Thus, the mito-
chondrial thymidine kinase is most likely re-
sponsible for the cytotoxicity of this agent by
converting it to a nucleotide. 5-Vinyl-dUrd and
E-5-propenyl-dUrd behave similarly toward hu-
man cytosol and mitochondrial thymidine ki-
nases. On the basis of the structural relationship,
it is conceivable that E-5-trifluoropropenyl-
dUrd and E-5-bromovinyl-dUrd may also have
a strong affinity to mitochondrial thymidine ki-
nase but not to the cytosol enzyme. Unpublished
results from this laboratory in collaboration with
R. T. Walker and E. DeClercq support this
notion. It should be noted that although the
cytosol thymidine kinase is not involved in the
cytotoxicity of E-5-propenyl-dUrd, it may play
an important role in the reversal process of the
cytotoxicity of this agent by dThd. Its role is
under current investigation.
The in vitro results presented here indicate
that the inclusion of a one-fifth equivalent of
dThd reverses the growth inhibitory activity of
E-5-propenyl-dUrd without decreasing its anti-
viral effects; even much higher levels of dThd
leave the virucidal activity unaffected. Since 5-
alkyl-dUrd analogs are generally substrates for
human dThd phosphorylase (unpublished data),
the combination of dThd with these analogs
could offer a second advantage, with dThd serv-
ing as a strong competitive substrate for the
phosphorylase and as a result prolonging the
action of the analogs. Although as yet untested
in vivo, this type of selective protection ap-
proach appears to have good potential in a va-
riety of applications for the treatment of HSV-
induced disease. For example, both E-5-bromo-
vinyl-dUrd and acyclovir (acycloguanosine)
have potent antiviral activity (8, 10, 12, 13), but
inhibit cell growth at higher concentrations. The
cytotoxic effects of E-5-bromovinyl-dUrd (and
other 5-substituted dUrd analogs) may be de-
creased or eliminated by the inclusion of dThd
(or other agents) without sacrificing the antiviral
activity. The mechanism may also be applied to
agents acting in related processes, such as acy-
clovir. Although the cytotoxic mechanism of
acyclovir has not been established, if it is me-
diated through the phosphorylation process
which nornally utilizes guanosine or deoxy-
guanosine, the inclusion of one of these with
acyclovir may minimize the cytotoxicity, leaving
its antiviral activity unaffected (since acyclovir
behaves as a dThd analog during its activation
in HSV-infected cells) (13). Further experiments
are needed to prove these points.
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